Lilly drug misses Phase III target

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

The Indiana drugmaker announced Wednesday that although the drug did not show a statistically significant gain over placebo for overall survival, results indicated “meaningful improvements” in secondary measures including progression-free survival and overall response rate.

ISI analyst Mark Schoenebaum said in April that a hepatocellular cancer indication could be worth around $200 million in sales.

The drug has orphan status for hepatocellular cancer. Lilly is also exploring the drug's use in other cancers, including non-small cell lung cancer.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.